Soleno Therapeutics (SLNO) announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Fulk brings to Soleno more than two decades of public company experience, with a career progression that includes 15 years at Eli Lilly (LLY).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Announces New Chief Financial Officer Appointment
- Soleno Therapeutics: Strong Early Vykat XR Traction, Rapid Market Penetration, and Expanding Growth Opportunities Support Buy Rating
- Soleno Therapeutics reports Q4 EPS 80c vs. ($1.27) last year
- SLNO Upcoming Earnings Report: What to Expect?
- Strategic Investment Fuels Confidence in Soleno Therapeutics’ Growth Outlook and Supports Buy Rating